Charles Schwab
DMTX

Charles Schwab’s Dimension Therapeutics, Inc DMTX Stock Holding History

Charles Schwab’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,100
Closed -$23K – 3231
2017
Q1 		$23K Hold
13,100
– – ﹤0.01% 3052
2016
Q4 		$57K Hold
13,100
– – ﹤0.01% 3066
2016
Q3 		$105K Hold
13,100
– – ﹤0.01% 3009
2016
Q2 		$79K Hold
13,100
– – ﹤0.01% 3073
2016
Q1 		$103K Hold
13,100
– – ﹤0.01% 2990
2015
Q4 		$148K Buy
+13,100
New +$166K ﹤0.01% 3009

Other funds holding DMTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Charles Schwab's DMTX Position: Q2 2017 in Review

Charles Schwab sold out of Dimension Therapeutics, Inc (DMTX) in Q2 2017, closing a stake of 13,100 shares — an estimated $23K sold.

Charles Schwab first reported a position in DMTX in Q4 2015 and held it in 6 quarters. The position peaked at $148K in Q4 2015. 35 funds tracked by Wall St. Rank hold DMTX as of Q2 2017.

  • Charles Schwab reported no remaining Dimension Therapeutics, Inc position as of Q2 2017 after selling out during the quarter.
  • Charles Schwab sold 13,100 Dimension Therapeutics, Inc shares in Q2 2017, an estimated $23K.
  • Charles Schwab first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 6 quarters.
  • Charles Schwab's Dimension Therapeutics, Inc position peaked at $148K in Q4 2015.
  • 35 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q2 2017.

Based on Charles Schwab's 13F filing for Q2 2017, filed 2 Aug 2017.